Compound News and Research

RSS

PolyMedix receives NIH grant to develop defensin-mimetic antimicrobial compounds for malaria

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a grant from the National Institute of Health (NIH) to support the development of defensin-mimetic antimicrobial compounds for the treatment of malaria.

7 Jul 2010

Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress

Nektar Therapeutics announced today that data presented at the European Society for Medical Oncology (ESMO) 12th World Congress on Gastrointestinal Cancer demonstrates that NKTR-102, the company's lead oncology compound, exhibits superior activity compared to irinotecan as part of either a monotherapy or combination regimen in tumor models of gastrointestinal cancers.

7 Jul 2010

Biotage launches AFFINILUTE Molecularly Imprinted Polymer columns for analytical sample preparation

Biotage, a leading supplier of tools and technology for analytical and medicinal chemistry, announced the introduction of high-performance, AFFINILUTE MIP (Molecularly Imprinted Polymers) columns for analytical sample preparation. Highly selective extractions with AFFINILUTE MIPs are considerably simplified resulting in faster, more robust and ultimately lower cost sample preparation.

7 Jul 2010

MabCent finds extraordinary life forms in the Arctic

During its short existence the Centre on Marine Bioactives and Drug Discovery (MabCent) in Tromsø has analysed some 70,000 fractions of Arctic marine organisms. Patents on two molecules have been applied for and applications for another 20 will soon follow.

3 Jul 2010

Studies demonstrate analgesic properties of synthetic cannabinoid

A new compound similar to the active component of marijuana (cannabis) might provide effective pain relief without the mental and physical side effects of cannabis, according to a study in the July issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

2 Jul 2010

QR Pharma to present clinical data from mechanism of action study in MCI patients at ICAD 2010

QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced today that it has been accepted to present a poster on clinical data from its recent mechanism of action study in mild cognitive impaired (MCI) patients at the International Congress on Alzheimer's Disease (ICAD 2010).

2 Jul 2010

Plant extract effective against ulcerative colitis in mice

A South Dakota State University scientist's research shows an extract made from a food plant in the Brassica family was effective in alleviating signs of ulcerative colitis, an inflammatory bowel condition, in mice.

2 Jul 2010

Parkinson's Disease Foundation awards $1.2M for research programs

The Parkinson's Disease Foundation (PDF) is pleased to announce awards totaling $1.2 million for research projects designed to understand the cause(s) of and find a cure for Parkinson's disease (PD).

2 Jul 2010

Anti-aging supplement: A fountain of hope for would-be mothers

According to the American Pregnancy Association, six million women a year deal with infertility. Now, a Tel Aviv University study is giving new hope to women who want to conceive ― in the form of a pill they can find on their drugstore shelves right now.

2 Jul 2010

Anthem submits new insurance rate plan in Calif. after earlier effort rebuffed

The Los Angeles Times: "Embattled health insurer Anthem Blue Cross is reviving its plan to raise rates for tens of thousands of California policyholders, some of whom could see their premiums rise as much as 20%. California's largest for-profit insurer submitted new rates Wednesday amid pressure to scale back increases of as much as 39% that had provoked fury from consumers, lawmakers and even President Obama" and helped revive the effort to pass a national health care law.

2 Jul 2010

Healthy diet can reduce age-related eye problems

While 20/20 vision is a symbol of visual acuity, between now and the year 2020, more and more people will experience some extent of vision loss due to age-related macular degeneration (AMD) and other sight-robbing diseases.

2 Jul 2010

Advanced Cancer Therapeutics secures $10M in investments

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, today announced that it has secured $10 million in investments from high net-worth individuals and institutions. This round of investment, which closed six months ahead of the company's year-end goal, will provide ACT additional capital to continue its development and commercialization of potentially lifesaving therapeutics for cancer patients.

2 Jul 2010

Research findings open new ways to enhance memory function and treat catastrophic brain diseases

For the first time, scientists have linked a brain compound called kynurenic acid to cognition, possibly opening doors for new ways to enhance memory function and treat catastrophic brain diseases, according to a new study from the University of Maryland School of Medicine. When researchers decreased the levels of kynurenic acid in the brains of mice, their cognition was shown to improve markedly, according to the study, which was published in the July issue of the journal Neuropsychopharmacology.

1 Jul 2010

Sanofi-aventis signs agreement to acquire TargeGen

TargeGen, Inc., a privately held biotechnology company focused on the development of small molecule kinase inhibitors today announced that the Company has agreed to be acquired by sanofi-aventis. Under the agreement, the ultimate purchase price will depend on the achievement of certain future milestones events and will total $560M if such milestones are fully realized. The closing of the transaction is expected to occur in the 3rd quarter of 2010.

1 Jul 2010

Bortezomib may offer hope for treating inflammatory diseases: New research

Those looking for a new treatment for a range of inflammatory diseases like arthritis, multiple sclerosis, inflammatory bowel disease, and lupus may need to look no further than a drug already available for treating cancer. In a research report published in the July 2010 print issue of the Journal of Leukocyte Biology, Japanese scientists use mice to show that bortezomib, currently used to treat cancers that affect white blood cells, induces cell death only in harmful (active and proliferating) T cells, leaving the rest unharmed.

1 Jul 2010

Investment report on BioCryst Pharmaceuticals

MicroStockProfit.com announces an investment report featuring BioCryst Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and recent company news that you need to know to make an educated investment decision.

30 Jun 2010

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Chelsea Therapeutics International, Ltd. has successfully reached its target enrollment of 150 patients in its Northera™ (Droxidopa) pivotal Phase III Study 301 for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH). Results from the trial are expected in September 2010 and the full registration program is on track to initiate a new drug application (NDA) in the first half of 2011.

30 Jun 2010

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

Transition Therapeutics Inc. announced today that the first patient has been dosed with drug candidate TT-301 in a Phase 1 clinical study. TT-301 is a small molecule compound that has demonstrated efficacy in preclinical models of rheumatoid arthritis, intracerebral haemorrhage and traumatic brain injury.

30 Jun 2010

New chemical method for drug design, agrichemicals

University of Delaware scientist Donald Watson is part of a research team that has discovered an easier method for incorporating fluorine into organic molecules, giving chemists an important new tool in developing materials ranging from new medicines to agricultural chemicals.

30 Jun 2010

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.

30 Jun 2010

Compound News and Research

PolyMedix receives NIH grant to develop defensin-mimetic antimicrobial compounds for malaria

Data on activity of Nektar's NKTR-102 in gastrointestinal cancer presented at ESMO 12th World Congress

Biotage launches AFFINILUTE Molecularly Imprinted Polymer columns for analytical sample preparation

MabCent finds extraordinary life forms in the Arctic

Studies demonstrate analgesic properties of synthetic cannabinoid

QR Pharma to present clinical data from mechanism of action study in MCI patients at ICAD 2010

Plant extract effective against ulcerative colitis in mice

Parkinson's Disease Foundation awards $1.2M for research programs

Anti-aging supplement: A fountain of hope for would-be mothers

Anthem submits new insurance rate plan in Calif. after earlier effort rebuffed

Healthy diet can reduce age-related eye problems

Advanced Cancer Therapeutics secures $10M in investments

Research findings open new ways to enhance memory function and treat catastrophic brain diseases

Sanofi-aventis signs agreement to acquire TargeGen

Bortezomib may offer hope for treating inflammatory diseases: New research

Investment report on BioCryst Pharmaceuticals

Chelsea completes enrollment in Northera Phase III Study 301 for neurogenic orthostatic hypotension

Transition commences dosing in TT-301 Phase 1 clinical study for rheumatoid arthritis, ICH, TBI

New chemical method for drug design, agrichemicals

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News